Protalix BioTherapeutics (NYSE:PLX) is scheduled to announce Q4 earnings results on Monday, March 17th, before market open. The consensus EPS Estimate is $0.07 (-22.2% Y/Y) and the consensus Revenue ...

M onday, H.C. Wainwright analysts increased their price target on Protalix BioTherapeutics (NYSE:PLX) stock to $15.00 from the previous $10.00 while continuing to recommend a Buy rating for the ...

Protalix BioTherapeutics stock opened at $2.52 on Tuesday. The stock has a market capitalization of $185.56 million, a price-to-earnings ratio of -19.38 and a beta of 0.75. Protalix ...

Explore Protalix BioTherapeutics stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for PLX. The Dow Jones closed lower by around 300 points on Friday.

Protalix Biotherapeutics, Inc. (NYSE:PLX) finds itself in an enviable position as we begin 2025. The company has two approved products generating revenues and a pipeline with multiple candidates ...

Chiesi and Protalix have built the case for their long-acting enzyme replacement therapy (ERT) for Fabry disease PRX-102, as the FDA’s review of the drug continues towards a decision due by 27 ...

Short interest in Protalix BioTherapeutics Inc (AMEX:PLX) increased during the last reporting period, rising from 3.99M to 4.30M. This put 6.1% of the company's publicly available shares short.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Sustainalytics’ Controversies Research identifies companies involved in incidents and events that may negatively impact stakeholders, the environment or the company’s operations. Controversies ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...